title: Exploring an Anabolic Approach to Address Nonunion After Bone Fracture: Commentary on an article by Brian A. Tinsley, MD, et al.: "Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model".
authors.affiliation: Orthopaedic Bioengineering Laboratory, Departments of Orthopaedic Surgery and Bioengineering, University of Louisville, Louisville, Kentucky.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Voor
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D005264:Femoral Fractures / Q000188:drug therapy*; D005593:Fracture Fixation, Internal; D006801:Humans; D008297:Male; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta